Evidence map›Paper›PMID 12228038›Full record

ReviewCurrent gastroenterology reports2002

Eosinophilic gastroenteritis.

Rahim Daneshjoo, Nicholas J Talley

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current gastroenterology reports, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 79 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Eosinophilic gastroenteritis: diagnosis and clinical perspectives.Clinical and experimental gastroenterology · 2019
    Review
  6. Evaluation of gene expression change in eosinophilic gastroenteritis.Gastroenterology and hepatology from bed to bench · 2019
    Article
  7. Article
  8. Eosinophilic gastroenteritis; a report of two cases with different presentations.Gastroenterology and hepatology from bed to bench · 2017
    Article
  9. Eosinophilic gastroenteritis: Approach to diagnosis and management.World journal of gastrointestinal pharmacology and therapeutics · 2016
    Review
  10. Article
  11. Clinical characteristics, treatment outcomes, and resource utilization in children and adults with eosinophilic gastroenteritis.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2015
    Article
  12. Article
  13. Article
  14. Article
  15. Rare case of ileal perforation.Journal of clinical and diagnostic research : JCDR · 2013
    Article
  16. Article
  17. Weight loss: only anorexia?Internal and emergency medicine · 2011
    Article
  18. Terminal ileitis is not always Crohn's disease.Annals of gastroenterology · 2011
    Review
  19. Ileitis: when it is not Crohn's disease.Current gastroenterology reports · 2010
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Rahim DaneshjooUniversity of Sydney, Nepean Hospital, Level 5 South Block, PO Box 63, Penrith NSW 2751, Australia.
Nicholas J Talley
Nepean Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eosinophilic gastroenteritis is a rare gastrointestinal (GI) disorder of undetermined cause characterized by infiltration of eosinophils in the GI tract. Eosinophils accumulate in tissues and may release highly cytotoxic granular proteins, which cause severe tissue damage characteristic of eosinophilic gastroenteritis. Eotaxin may play a role in the recruitment of eosinophils into tissue in combination with chemoattractants and cytokines, including interleukin 3 and 5 and granulocyte-macrophage colony-stimulating factor. Food allergy, especially in children, can be a triggering factor, and an amino acid-based diet may be helpful. Accumulation of eosinophils in the gut is a common feature in food-induced GI disorders that can be regulated through a complex molecular network involving Th2 cells, various cytokines, and chemokines. Eosinophilic gastroenteritis has a wide spectrum of clinical presentation depending on the site of involvement. It may be confused with irritable bowel syndrome or dyspepsia and, rarely, mimics pancreatitis or appendicitis. Diagnosis is important and is usually made by a pathologist. Eosinophilic gastroenteritis is a treatable disease; patients generally respond to steroid therapy, although relapse is common. Non-enteric-coated budesonide, a locally acting corticosteroid with little risk of adrenal suppression, may be substituted, although more experience is needed. Promising new drugs for eosinophilic gastroenteritis include montelukast, a selective leukotriene receptor antagonist, and suplaplast tosilate, a selective Th2 cytokine inhibitor with inhibitory effects on allergy-induced eosinophilic infiltration and IgE production. Although it is likely a separate disease, more experience has accumulated, and an elimination or specific amino acid-based diet appears to be helpful in treatment.

Indexed as

AdultAnimalsChemotactic Factors, EosinophilChildChild, PreschoolClinical Trials as TopicCytokinesDrug-Related Side Effects and Adverse ReactionsEosinophiliaFemaleFood HypersensitivityGastroenteritisHumansMaleParasitic DiseasesPrognosisChemotactic Factors, EosinophilCytokines

Identifiers

PMID12228038
OpenAlexW3188842109

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.